AMED - Amedisys, Inc.
| Previous Close | 188.87 |
| Open | 186.38 |
| Bid | 193.09 x 1100 |
| Ask | 193.07 x 1300 |
| Day's Range | 184.58 - 196.33 |
| 52 Week Range | 106.65 - 202.76 |
| Volume | 216,184 |
| Avg. Volume | 209,890 |
| Market Cap | 6.145B |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | 49.52 |
| EPS (TTM) | 3.84 |
| Earnings Date | Apr 27, 2020 - May 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 214.75 |
- GlobeNewswire
Amedisys to Present at the Raymond James 41st Annual Institutional Investors Conference
BATON ROUGE, La., Feb. 25, 2020 -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B..
- Zacks
3 Reasons Growth Investors Will Love Amedisys (AMED)
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
- Thomson Reuters StreetEvents
Edited Transcript of AMED earnings conference call or presentation 19-Feb-20 4:00pm GMT
Q4 2019 Amedisys Inc Earnings Call
- Zacks
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Simply Wall St.
Amedisys, Inc. Analysts Are Pretty Bullish On The Stock After Recent Results
Last week, you might have seen that Amedisys, Inc. (NASDAQ:AMED) released its full-year result to the market. The...
- Zacks
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
- Investor's Business Daily
Dow Jones Futures: AMD Ignores Apple-Led Retreat; Enphase, SolarEdge, Amedisys, 10X Genomics, Palomar Are Key Movers
Futures: Enphase, Amedisys, 10X Genomics, Palomar were earnings movers overnight. Earlier, AMD showed why investors should focus on the best stocks from the best groups.
- GlobeNewswire
Amedisys Reports Fourth Quarter and Year End 2019 Financial Results and Issues 2020 Guidance
BATON ROUGE, La., Feb. 18, 2020 -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three month period and year ended December 31, 2019. Three.
- Zacks
Why Amedisys (AMED) is Poised to Beat Earnings Estimates Again
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
Amedisys (AMED) Outpaces Stock Market Gains: What You Should Know
Amedisys (AMED) closed the most recent trading day at $195.13, moving +1.28% from the previous trading session.
- Zacks
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investor's Business Daily
Why You Should Keep An Eye On These 5 Leading Health Care Stocks
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
- GlobeNewswire
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date
Amedisys, Inc. (AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2019, after the market closes on February 18, 2020. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 19, 2020. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
- Simply Wall St.
Is Amedisys, Inc. (NASDAQ:AMED) Overpaying Its CEO?
Paul Kusserow became the CEO of Amedisys, Inc. (NASDAQ:AMED) in 2014. This analysis aims first to contrast CEO...
- GuruFocus.com
Eaton Vance Exits Celgene, Trims Amgen Position
Health care-focused fund's largest sales of the 4th quarter Continue reading...
- Zacks
Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Zacks
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
- Zacks
Buy These 5 Low Leverage Stocks This Earnings Season
With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.
- Zacks
The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group
The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group
- Zacks
Year of the Rat Spells Good Times for Wall Street: 5 Picks
Historically, during the Year of the Rat, the S&P 500's performance has been slightly better than the than the index's overall average of 11.4%.
- Zacks
Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?
Is (AMED) Outperforming Other Medical Stocks This Year?
- Zacks
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
- Zacks
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
